Cargando…

Early Surgery Prolongs Professional Activity in IDH Mutant Low-Grade Glioma Patients: A Policy Change Analysis

BACKGROUND: Until 2015, Dutch guidelines recommended follow-up and biopsy rather than surgery as initial care for suspected low-grade gliomas (LGG). Given evidence that surgery could extend patient survival, our center stopped following this guideline on January 1, 2010 and opted for early maximal s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robe, Pierre A., Rados, Matea, Spliet, Wim G., Hoff, Reinier G., Gosselaar, Peter, Broekman, Marike L. D., van Zandvoort, Martine J., Seute, Tatjana, Snijders, Tom J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959843/ https://www.ncbi.nlm.nih.gov/pubmed/35356212 http://dx.doi.org/10.3389/fonc.2022.851803

Ejemplares similares

Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma
por: van Kessel, Emma, et al.
Publicado: (2022)

Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples
por: Berendsen, Sharon, et al.
Publicado: (2019)

Added Value of Cognition in the Prediction of Survival in Low and High Grade Glioma
por: van Kessel, Emma, et al.
Publicado: (2021)

Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study
por: van Kessel, Emma, et al.
Publicado: (2019)

Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment
por: van Kessel, Emma, et al.
Publicado: (2019)

Epilepsy Associates with Decreased HIF-1α/STAT5b Signaling in Glioblastoma
por: Berendsen, Sharon, et al.
Publicado: (2019)

Cognitive impairments are independently associated with shorter survival in diffuse glioma patients
por: van Kessel, Emma, et al.
Publicado: (2020)

STAT5b is a marker of poor prognosis, rather than a therapeutic target in glioblastomas
por: Dubois, Nadège, et al.
Publicado: (2022)

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas
por: Liu, Yanwei, et al.
Publicado: (2022)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma
por: Dankbaar, J. W., et al.
Publicado: (2015)

Complications, compliance, and undertreatment do not explain the relationship between cognition and survival in diffuse glioma patients
por: van Kessel, Emma, et al.
Publicado: (2022)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Prognosis and therapy of tumor-related versus non-tumor-related status epilepticus: a systematic review and meta-analysis
por: Arik, Yunus, et al.
Publicado: (2014)

Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment
por: van Kessel, Emma, et al.
Publicado: (2017)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

Conventional MRI Criteria to Differentiate Progressive Disease From Treatment-Induced Effects in High-Grade (WHO Grade 3–4) Gliomas
por: Flies, Christina M., et al.
Publicado: (2022)

MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma
por: Molloy, Abigail R, et al.
Publicado: (2020)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
por: Radoul, Marina, et al.
Publicado: (2021)

CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
por: Ohba, Shigeo, et al.
Publicado: (2022)

METABOLOGENOMIC CHARACTERIZATION UNCOVERS HETEROGENEITY AMONG IDH MUTANT GLIOMAS
por: Ajisebutu, Andrew, et al.
Publicado: (2023)

IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice
por: Richardson, Leland G., et al.
Publicado: (2020)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

IGFBP2 expression predicts IDH-mutant glioma patient survival
por: Huang, Lin Eric, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1f12rlmslpsk5jgj0ik8snljsn